MREO
Companies
NASDAQ
Mereo BioPharma Group plc - ADR
Health Care
$2.87
-$0.63 (-18.00%)
Price Chart
Overview
About MREO
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Market Cap
$479.7M
Volume
4.1M
Avg. Volume
4.1M
P/E Ratio
-63.5
Dividend Yield
0.00%
Employees
34.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.88
Moderate Correlation
Volatility
High (0.63)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, MREO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$479.7M
Volume4.1M
P/E Ratio-63.50
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 31, 2021Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025